Jan 18, 2023
Findings from a new series of studies could hold broad implications for developing vaccines against enteric pathogens.
Enterotoxigenic Escherichia coli (ETEC) and Shigella are two of the top five pathogens that cause moderate and severe diarrhea among children in Africa and South Asia. Typically caused by contaminated food or water, infections can lead to severe dehydration and death. Repeated infections can stunt children’s physical and cognitive development, causing a cascading burden with long-term consequences.
In low-income countries, access to medical treatment is often limited. On top of this challenge, bacterial resistance to antibiotics is growing. Vaccines that prevent ETEC and Shigella, which are currently under development, hold dramatic potential for reducing disease burden. PATH is collaborating with partners around the globe on advancing research on several vaccine candidates in the laboratory and through clinical trials.
Shigella: A survivor's Story
Global research and partnerships are advancing the development of safe, effective, and affordable vaccines against ETEC and Shigella pathogens. If introduced in high-burden countries or sub-national regions once they are available, these vaccines are projected to have a significant public health impact.